The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country


Creative Commons License

Toy M., ÖNDER F. O. , İDİLMAN R., Kabacam G., Richardus J. H. , Bozdayi M., ...More

EUROPEAN JOURNAL OF HEALTH ECONOMICS, vol.13, no.5, pp.663-676, 2012 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1007/s10198-012-0413-8
  • Journal Name: EUROPEAN JOURNAL OF HEALTH ECONOMICS
  • Journal Indexes: Social Sciences Citation Index
  • Page Numbers: pp.663-676
  • Keywords: Chronic hepatitis B, Cost-effectiveness analysis, Antiviral therapy, Turkey, Middle income, NUCLEOSIDE-NAIVE PATIENTS, ADEFOVIR DIPIVOXIL, PEGINTERFERON ALPHA-2A, TREATMENT ALTERNATIVES, COMPENSATED CIRRHOSIS, VIROLOGICAL RESPONSE, LAMIVUDINE TREATMENT, SUSTAINED RESPONSE, NATURAL-HISTORY, RESISTANCE

Abstract

Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness.